B6-hSNCA (3'UTR) Mouse
Product Name
B6-hSNCA (3'UTR) Mouse
Product ID
C001698
Strain Name
C57BL/6NCya-Sncatm2(hSNCA)/Cya
Backgroud
C57BL/6NCya
Status
When using this mouse strain in a publication, please cite “B6-hSNCA (3'UTR) Mouse (Catalog C001698) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Gene Name
SNCA
Gene Alias
PD1, NACP, PARK1, PARK4
NCBI ID
Chromosome
Chr 4 (Human)
MGI ID
Datasheet
Strain Description
Parkinson's disease (PD) is a neurodegenerative disease with a high prevalence mainly in the middle-aged and elderly population. It is the second most common neurodegenerative disease after Alzheimer's disease (AD). The main clinical symptoms include resting tremors, limb stiffness, bradykinesia, loss of voluntary movement, etc. The typical pathological process of PD is the formation of Lewy bodies (LB) in the central nervous system (CNS), which results in the gradual death and loss of dopaminergic neurons, leading to the disease [1-2]. The main components of Lewy bodies are insoluble aggregates of abnormal α-synuclein (α-syn), and the SNCA gene, which encodes α-synuclein, is one of the key causative genes in Parkinson's disease. Mutations in this gene cause overexpression of α-syn, leading to Lewy bodies' formation, ultimately leading to PD [3]. In addition, SNCA mutations are also associated with diseases such as dementia with Lewy bodies (DLB) and multiple system atrophy (MSA).
The B6-hSNCA (3'UTR) mouse is a humanized model constructed by replacing the mouse Snca gene in situ with the human SNCA gene, in which the sequences from ATG start codon to downstream of 3'UTR of the endogenous mouse Snca gene are replaced with the sequences from ATG start codon to downstream of 3'UTR of the human SNCA gene. The homozygous B6-hSNCA (3'UTR) mice are viable and fertile and can be used for studies on Parkinson's disease (PD), Dementia with Lewy Bodies (DLB) and Multiple System Atrophy (MSA), and pathogenesis of neurodegenerative diseases, as well as for SNCA-targeted drug development.
Reference
Bonini NM, Giasson BI. Snaring the function of alpha-synuclein. Cell. 2005 Nov 4;123(3):359-61.
Chandra S, Gallardo G, Fernández-Chacón R, Schlüter OM, Südhof TC. Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell. 2005 Nov 4;123(3):383-96.
Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997 Jun 27;276(5321):2045-7.
Strain Strategy
The sequences from ATG start codon to downstream of 3'UTR of the endogenous mouse Snca gene were replaced with the sequences from ATG start codon to downstream of 3'UTR of the human SNCA gene.
Figure 1. Gene editing strategy of B6-hSNCA (3'UTR) Mice.
Application Area
Parkinson's disease (PD) pathogenic mechanism research;
Parkinson's disease (PD) therapeutic drug development and efficacy verification;
Dementia with Lewy Bodies (DLB) and Multiple System Atrophy (MSA) study.
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
